Synta
Pharmaceuticals Corp. (Nasdaq: SNTA) terminated its Phase 3 GALAXY-2 trial of
ganetespib and docetaxel to treat advanced lung cancer. Shares of the biopharmaceutical collapsed $1.47 to $0.57.
Synta terminates clinical trial
October 21, 2015 at 13:00 PM EDT
